News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

MTM Laboratories AG Announces That 68 Abstracts Will Be Presented At USCAP Detailing The Utility Of P16 Across Multiple Clinical Applications

3/18/2010 3:56:45 PM

Heidelberg, Germany- March 18, 2010- mtm laboratories today announced that there will be 68 different abstracts or presentations from independent clinical researchers detailing the value of using p16 in a variety of tissue types presented next week at the 99th United States & Canadian Academy of Pathology (USCAP) annual meeting in Washington, DC. Of these abstracts, 22 address the use of p16 in gynecological tissue specimens. The additional 46 present the growing body of evidence on the value and expanded use of p16 in tissues other than gynecological specimens including: head and neck, lung, breast, bladder, and GI.

mtm laboratories’ CINtec® Histology assay is based on the specifically designed antibody clone E6H4™ as the method for identifying p16INK4a in histological specimens. The sensitivity and specificity of the E6H4™ antibody clone has been established and validated and published in over 100 clinical papers. The primary area of application is in Cervical Cancer Screening and Diagnosis, with a host of emerging applications. GMP manufactured kit components in combination with the optimized antibody ensures the reproducible quality and results in assessing a wide variety of biological specimens.

Bob Silverman, CEO of mtm laboratories said: “We are very pleased to see this high a level of independent abstracts focused on p16 accepted for this year’s USCAP meeting. The extent and breadth of these research studies solidly demonstrate the growing recognition of the potential utility of p16 and the CINtec® Histology kit within the anatomic pathology community.”

About mtm laboratories AG

mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at:

Read at

comments powered by Disqus